In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Genocea Biosciences (GNCA), with a price target of $42. The company’s shares closed on Friday at $5.61.
Pantginis observed:
“Valuation and risks to price target achievement. We reiterate our Buy rating and are increasing our price target to $42 from $5.75. The factors impacting our target change include: (1) adjustment to base year; and (2) adjustment to fully diluted share count subsequent to the 8 reverse split.”
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -5.1% and a 33.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
Currently, the analyst consensus on Genocea Biosciences is a Moderate Buy with an average price target of $42.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.16 and a one-year low of $2.24. Currently, Genocea Biosciences has an average volume of 476.5K.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GNCA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses.
